ArticleAntibiotics (Basel, Switzerland)2024
Synergistic Antimicrobial Activity of Biogenic Silver Nanoparticles and
Article in Antibiotics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Managing Malassezia species and related infections: new insights into recent natural and synthetic antifungal compounds and their mechanism of action.Molecular diversity · 2026Review
- Nanoformulations of essential oils for the treatment of fungal diseases, with a focus on dermatophytes.Archives of microbiology · 2026Review
- Harnessing biogenic nanoparticles for combating antibiotic resistance: green synthesis, mechanistic insights, and biotechnological applications.Frontiers in bioengineering and biotechnology · 2026Review
- Review
- Antibacterial synergistic behaviour of phytosynthesized magnesium oxide nanoparticles with clove essential oil.Scientific reports · 2025Article
- Anti-inflammatory activity of Acanthospermum australe: Insights from network pharmacology, chemical analysis, and in vitro assays.PloS one · 2025Article
- Silver Nanoparticles in Therapeutics and Beyond: A Review of Mechanism Insights and Applications.Nanomaterials (Basel, Switzerland) · 2024Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In response to the steady increase in antimicrobial-resistant strains, the World Health Organisation has emphasised the need to investigate new antimicrobial agents and alternative therapies that improve the spectrum of activity and reduce the dose required, thus improving safety. This study focused on the characterisation of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.